Tempest Therapeutics Enters Into Exclusive Option Agreement To License Senlang's CD7-Targeted Lentiviral Vector Platform And Portfolio Of In Vivo CAR-T Product Candidates
Share
Why It Matters
Tempest made a deal to use special cancer-fighting cell technology from another company. When companies team up like this, it shows they believe in the science and may have new products coming.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.